Polaryx Therapeutics Common Stock Overview
Valuation check: PLYX's P/E ratio is -16.52, below the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow-16.52
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Polaryx Therapeutics Common Stock's p/e ratio stands at -16.52. That is below the Healthcare sector average of 24.78. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Polaryx Therapeutics Common Stock sits lower the Healthcare benchmark (24.78) with a P/E ratio of -16.52. That is roughly 166.7% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether -16.52 is attractive depends on Polaryx Therapeutics Common Stock's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Polaryx Therapeutics Common Stock's P/E ratio evolved across reporting periods, while the comparison chart places PLYX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Polaryx Therapeutics Common Stock's reading of -16.52 (sector avg 24.78) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
